- Therapeutic Effectiveness of Interferon-a2b Against COVID-19: The Cuban Experience
- An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients
- Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19
- COVID-19 Lethality in Sub-Saharan Africa and Helminth Immune Modulation
- Association of Early Nasopharyngeal Immune Markers With COVID-19 Clinical Outcome: Predictive Value of CCL2/MCP-1
- CIGB-258 immunomodulatory peptide: a novel promising treatment for critical and severe COVID-19 patients
- Interferon gamma, TGF-β1 and RANTES expression in upper airway samples from SARS-CoV-2 infected patients
- La industria biofarmacéutica cubana en el combate contra la pandemia de COVID-19
- Publicaciones
Covid-19: Resultado de Ensayos Clinicos
- – REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. NCT04425629.
- – SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. NCT04427501.
- – Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. NCT04436276.
- – Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. NCT04338360.
- – Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. NCT04470427.